Ormeloxifene, also known as centchroman, is one of the selective estrogen receptor modulators, or SERMs, a class of medication which acts on the estrogen receptor. It is best known as a nonsteroidal oral contraceptive which is taken once per week. Chemically it is a benzopyran derivative with tissue selective estrogen receptor activity that produces contraceptive effects primarily by altering endometrial receptivity and modulating tubal and uterine motility rather than by suppressing ovulation; this pharmacology underlies its once weekly dosing and a prolonged pharmacodynamic profile. In pharmaceutical use the active pharmaceutical ingredient is supplied as 30 mg tablets in many markets, and typical clinical uses include contraception and management of certain menstrual disorders; analytical characterization for quality control commonly relies on reversed phase HPLC for assay and related-compound profiling and LC-MS for structural confirmation.
Parent: Ormeloxifene
Typical quality specifications for Ormeloxifene API and finished product follow standard pharmaceutical impurity control principles: assay is commonly specified around 98.0 to 102.0 percent of labelled amount, total impurities are generally limited to not more than 1.0 percent, and any single unspecified impurity is commonly limited to 0.2 percent or less; known related compounds such as N-desmethyl ormeloxifene, hydroxylated derivatives, and certain ring-modified chromene congeners are controlled individually and often limited to 0.5 percent or lower depending on regulatory filing. Process- and degradation-related impurities are monitored along with residual solvents by GC and elemental impurities by ICP techniques. Typical analytical approaches used to quantify and identify these species include validated HPLC impurity methods with UV detection, orthogonal LC-MS for identity confirmation, and stability studies to define acceptable limits over shelf life.
Ormeloxifene is used primarily as a once-weekly oral contraceptive and in some regions for treatment of certain menstrual disorders such as dysfunctional uterine bleeding; it acts as a selective estrogen receptor modulator producing contraceptive effect through changes in the endometrium and uterine/tubal function rather than by consistently inhibiting ovulation.
Yes, Saheli is a marketed brand name for centchroman in some regions and the product marketed as Saheli contains ormeloxifene as the active ingredient; always verify the product label and local regulatory information for exact strength and manufacturer details.
Onset of contraceptive protection depends on the regimen and timing of initiation; because of its pharmacodynamic properties and recommended regimens, clinical protection is generally established after the initial loading period described in product labeling, so consult the approved prescribing information for precise guidance and use additional contraception as directed during the initiation phase.
